Amendment No. 1 to Consulting Agreement between Cue Biopharma, Inc. and Peter Kiener D.Phil

Contract Categories: Human Resources › Consulting Agreements
Summary

Cue Biopharma, Inc. and consultant Peter Kiener D.Phil have amended their original consulting agreement, effective September 1, 2023. The amendment changes the monthly retainer to $9,166.67 for at least 20 hours of consulting services per month. All other terms of the original agreement remain unchanged. Both parties have agreed that the original agreement and this amendment together form a single, unified contract.

Read More Arrow
EX-10.1 2 cue-ex10_1.htm EX-10.1 EX-10.1

 

 

 

 

EXHIBIT 10.1

 

AMENDMENT NO. 1 TO CONSULTING AGREEMENT

 

THIS AMENDMENT NO. 1 TO CONSULTING AGREEMENT (this “Amendment No. 1”)

effective September 1, 2023 is entered into between Cue Biopharma, Inc., a Delaware corporation having an address of 40 Guest Street, Boston MA 02135 (the “Company”), and Peter Kiener D.Phil, (“Consultant”) whose address is [**}. Company and Consultant may be referred to herein individually as “Party” or jointly as “Parties.”

 

Whereas the Parties executed a Consulting Agreement having an effective date of June 7, 2023, and now wish to revise Exhibit A of the Consulting Agreement to amend the monthly retainer to be provided to the Consultant, the Parties hereby agree as follows:

 

1.
Exhibit A is amended as follows:

 

Consultant will provide agreed upon services for at least 20 hours per month for a monthly retainer of $9,166.67

 

2.
Except as amended herein, all of the terms, provisions and conditions set forth in the original Consulting Agreement are hereby confirmed and shall remain in full force and effect. The original Consulting Agreement and this Amendment No. 1 shall be read and construed together as a single agreement and the term “Agreement” as used shall henceforth be deemed a reference to the original Consulting Agreement as amended by this Amendment No. 1.

 

3.
Counterparts. This Amendment No. 1 may be signed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

 

 

 

 

 

THE COMPANY

 

Cue Biopharma, Inc.



 

 

CONSULTANT

 

Peter A Kiener, D.Phil

 

 

 

 

 

 

/s/ Daniel R. Passeri

/s/ Peter Kiener

Name: Daniel R. Passeri

Name: Peter A Kiener, D. Phil

Title: Chief Executive Officer

Title: Consultant

(Principal Executive Officer)